BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number: BE2016C059I2
Authority: BE; Belgium

Application number

BE2016C059C

Other languages

Dutch (nl)

Original Assignee

Novozymes Biopharma Dk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2016-11-04

Publication date

2020-08-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-11-04 Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As

2020-08-20 Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Hematology (AREA)

BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US19938400P	2000-04-25	2000-04-25
US25693100P	2000-12-21	2000-12-21
EP06076852A EP1832599A3 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
EP08075909A EP2067488A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
EP01934875A EP1278767A4 (en)	2000-04-12	2001-04-12	ALBUMIN FUSION PROTEINS

Publications (1)

Publication Number	Publication Date
BE2016C059I2 true BE2016C059I2 (en)	2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2016C059C BE2016C059I2 (en)	2000-04-12	2016-11-04

Country Status (10)

Country	Link
US (23)	US6926898B2 (en)
EP (21)	EP2213743A1 (en)
JP (9)	JP2004506407A (en)
AU (7)	AU2001259066A1 (en)
BE (1)	BE2016C059I2 (en)
CA (8)	CA2405557C (en)
DK (2)	DK2236152T3 (en)
ES (2)	ES2529300T3 (en)
FR (1)	FR16C0043I2 (en)
WO (7)	WO2001079442A2 (en)

Families Citing this family (676)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (en)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2001034769A2 (en) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	24 human secreted proteins
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (en) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Human and murine semaphorin L
US20030022293A1 (en) *	1997-09-18	2003-01-30	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
DE69933216T2 (en) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
US6818611B1 (en)	1998-10-13	2004-11-16	University Of Georgia Research Foundation, Inc.	Stabilized bioactive peptides and methods of identification, synthesis and use
ATE320486T1 (en) *	1999-05-05	2006-04-15	Phylogica Ltd	ISOLATION OF BIOLOGICAL MODULATORS FROM LIBRARIES WITH BIOLOGICALLY DIVERSE GENE FRAGMENTS
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
JP2003528587A (en) *	1999-10-29	2003-09-30	ヒューマンジノームサイエンシーズ，インコーポレイテッド	27 human secretory proteins
AU1449001A (en) *	1999-11-05	2001-06-06	Human Genome Sciences, Inc.	28 human secreted proteins
CA2389724A1 (en) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	28 human secreted proteins
DK1234031T3 (en)	1999-11-30	2017-07-03	Mayo Foundation	B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
EP1240337B1 (en)	1999-12-24	2006-08-23	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
EP1285066A1 (en) *	2000-05-12	2003-02-26	MERCK PATENT GmbH	F-box containing protein
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
US6965018B2 (en)	2000-06-06	2005-11-15	Bristol-Myers Squibb Company	Antibodies directed to B7-related polypeptide, BSL-2
EP1283886A2 (en) *	2000-06-08	2003-02-19	Incyte Genomics, Inc.	Intracellular signaling proteins
MXPA02012717A (en) *	2000-06-21	2003-09-22	Amgen Inc	COLON STROMATIC POLYPEPTIDES-1, EPITELIALS, SECRETS, NUCLEIC ACIDS CODING THEM AND THEIR USES.
AU2001229507A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	21 human secreted proteins
CA2419306A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	23 human secreted proteins
CA2418680A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	11 human secreted proteins
CA2420902A1 (en) *	2000-08-28	2002-03-07	Craig A. Rosen	18 human secreted proteins
CA2420192A1 (en) *	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 human secreted proteins
CA2421147A1 (en) *	2000-09-29	2002-04-11	Human Genome Sciences, Inc.	24 human secreted proteins
WO2002031111A2 (en) *	2000-10-12	2002-04-18	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (en) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	RENIN AND / OR PRORENIN RECEPTOR PROTEIN, NUCLEIC ACID ENCODING THE RECEPTOR AND THEIR APPLICATIONS
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
WO2002046228A2 (en) *	2000-12-05	2002-06-13	Wisconsin Alumni Research Foundation	Receptor for b. anthracis toxin
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
JP4344519B2 (en) *	2000-12-28	2009-10-14	旭化成ファーマ株式会社	NF-κB activating gene
EP1368468A4 (en) *	2001-02-23	2005-02-16	Human Genome Sciences Inc	83 HUMAN SECRETED PROTEINS
WO2002072138A1 (en) *	2001-03-08	2002-09-19	Hyseq, Inc.	Methods and materials relating to fibulin-like polypeptides and polynucleotides
WO2002083921A2 (en)	2001-04-10	2002-10-24	Agensys, Inc.	Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US7164007B2 (en)	2001-06-20	2007-01-16	Genentech, Inc.	Anti-PR020044 antibodies
AU2002328853A1 (en) *	2001-07-06	2003-01-21	Geneprot, Inc.	Carcinoma-related peptides
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
AU2002332041A1 (en) *	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (en)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström syndrome gene, gene variants, encoded protein and method for diagnosing Alström syndrome
KR100406760B1 (en) *	2001-11-16	2003-11-21	신코엠 주식회사	Semiconductor memory device
EP1458756B1 (en)	2001-12-17	2009-01-28	Laboratoires Serono SA	Chemokine mutants acting as chemokine antagonists
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
AU2002364586A1 (en) *	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
WO2003066824A2 (en) *	2002-02-07	2003-08-14	Aventis Behring Gmbh	Albumin-fused kunitz domain peptides
DE10205520A1 (en) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitory, monoclonal antibody against the clotting factor VII activating protease
BR0307871A (en) *	2002-02-21	2005-04-12	Wyeth Corp	Folistatin Domain-Containing Proteins
EP1483580A4 (en) *	2002-03-05	2006-10-11	Merck & Co Inc	BIOLOGICAL MARKER INDICATING THE EFFECTIVENESS OF HUNGER DRUGS
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003231731A1 (en) *	2002-04-15	2003-11-03	American National Red Cross	Method for detecting ligands and targets in a mixture
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
WO2003089608A2 (en)	2002-04-18	2003-10-30	The General Hospital Corporation	Drg11-responsive (dragon) gene family
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en)	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
ES2348230T3 (en)	2002-06-07	2010-12-01	Dyax Corp.	PREVENTION AND REDUCTION OF THE ISCHEMIA.
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
DK1531850T3 (en) *	2002-06-07	2012-06-04	Zymogenetics Inc	Use of 1L-21 and monoclonal antibody for the treatment of solid cancers
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
CN101172091B (en) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	Preparation process and application of fusion protein skin care product containing human serum albumin and skin cell growth factor
AU2003245090A1 (en) *	2002-07-03	2004-01-23	Nexgen Biotechnologies, Inc.	Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
WO2004004649A2 (en) *	2002-07-08	2004-01-15	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
WO2004009626A1 (en) *	2002-07-22	2004-01-29	Yamanouchi Pharmaceutical Co., Ltd.	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
CA2496002A1 (en) *	2002-08-07	2004-02-19	Delta Biotechnology Ltd.	Albumin-fused ciliary neurotrophic factor
AU2003255276A1 (en) *	2002-08-13	2004-02-25	Arbios Systems, Inc.	Selective plasma exchange therapy
EP2386310B1 (en)	2002-08-28	2018-11-07	Dyax Corp.	Methods for preserving organs and tissues
JP4601426B2 (en) *	2002-09-06	2010-12-22	アレクシオンファーマシューティカルズ，インコーポレイテッド	Method for the treatment of asthma using antibodies against complement component C5
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
KR20050071498A (en) *	2002-09-18	2005-07-07	상트르 오스피딸리에 드 루니버시떼 드 몬트리알	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (en)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Gene products differentially expressed in tumors and their use
AU2003292273A1 (en) *	2002-12-20	2004-07-14	Karolinska Institutet Innovations Ab	Asthma susceptibility locus
EP1577322A4 (en) *	2002-12-26	2006-01-25	Takeda Pharmaceutical	NEW PROTEINS AND THEIR USE
CA2515708A1 (en) *	2003-02-11	2004-08-26	Transkaryotic Therapies, Inc.	Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
EP1606305A4 (en) *	2003-03-12	2009-06-24	Vasgene Therapeutics Inc	Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082640A2 (en) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Human serum albumin conjugates with therapeutic compounds
KR20060017585A (en) *	2003-04-04	2006-02-24	유니베르시떼 드 로잔느	Peptides for Cancer Treatment
AU2004229501B2 (en)	2003-04-11	2011-08-18	Medimmune, Llc	Recombinant IL-9 antibodies and uses thereof
WO2004094589A2 (en) *	2003-04-18	2004-11-04	Incyte Corporation	Secreted proteins
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
US7517655B2 (en) *	2003-06-30	2009-04-14	Nihon University	Protein capable of deposition onto extracellular matrix
US7393534B2 (en)	2003-07-15	2008-07-01	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
ATE447412T1 (en)	2003-11-04	2009-11-15	Novartis Vaccines & Diagnostic	ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS OF USE
ES2380022T3 (en) *	2003-12-03	2012-05-07	Monika KRÖZ	Interleukin-11 fusion proteins
CN100379762C (en) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	Fusion protein of human serum albumin and interleukin 2 and its coding gene
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7371381B2 (en)	2003-12-12	2008-05-13	Amgen Inc.	Anti-galanin antibodies and uses thereof
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
WO2006067511A1 (en)	2004-12-23	2006-06-29	Novozymes Delta Limited	Gene expression technique
EP1712619A4 (en) *	2003-12-24	2008-01-02	Takeda Pharmaceutical	SUBSTANCE FOR THE PREVENTION AND TREATMENT OF CANCER
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
SE0400489D0 (en) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
EP1721008B1 (en) *	2004-03-03	2010-02-24	EVOTEC Neurosciences GmbH	Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
AU2005227192A1 (en) *	2004-03-11	2005-10-06	Kythera Biopharmaceuticals, Inc.	Compositions and methods for preventing and treating skin and hair conditions
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
DK1730196T3 (en)	2004-03-12	2011-03-28	Vasgene Therapeutics Inc	EphB4-binding antibodies to inhibit antiogenesis and tumor growth
US9592277B2 (en) *	2004-04-14	2017-03-14	Avirid, Inc.	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
HRP20060362A2 (en) *	2004-04-23	2007-03-31	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
KR100599454B1 (en) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	New Uses of AIM3 to Act as Tumor Suppressor
DE102004024617A1 (en)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentially expressed in tumors gene products and their use
EP1756554A4 (en) *	2004-06-03	2009-04-29	Vermillion Inc	BIOMARKERS FOR PERIPHERAL ARTERIOPATHY (PA)
CA2578709C (en) *	2004-06-17	2010-06-15	Virun, Inc.	Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
EP1773375A1 (en)	2004-07-14	2007-04-18	University of Utah Research Foundation	Netrin-related compositions and uses
CN101018874A (en) *	2004-08-13	2007-08-15	千年药品公司	Genes, compositions, kits and methods for identifying, evaluating, preventing and treating prostate cancer
EP1793850A4 (en)	2004-09-21	2010-06-30	Medimmune Inc	ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUSES AND METHODS OF PRODUCING THE VACCINES THEREFOR
CA2581423A1 (en) *	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060078541A1 (en) *	2004-10-01	2006-04-13	Giles Brian C	Method and formula for stem cells' stimulation, targeting release, trafficking and homing
DK1810026T3 (en)	2004-10-06	2018-07-16	Mayo Found Medical Education & Res	B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
WO2006042197A2 (en) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Use of del-1 in hair, bone and cartilage regeneration
JP5036546B2 (en)	2004-10-25	2012-09-26	イミューンシステムキーリミテッド	Thymus-specific protein
KR100583350B1 (en) *	2004-11-03	2006-06-05	(주)넥스젠	Method for producing epithelial cell regeneration factor using a fusion protein containing FAS-1 domain
DE602005009856D1 (en) *	2004-11-09	2008-10-30	Ares Trading Sa	PROCESS FOR CLEANING FSH
US20090196850A1 (en)	2005-01-06	2009-08-06	Novo Nordisk A/S	Anti-Kir Combination Treatments and Methods
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
HUE025945T2 (en)	2005-02-15	2016-07-28	Univ Duke	Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
EP1864138A2 (en) *	2005-03-23	2007-12-12	Wyeth	Detection of gdf-8 modulating agents
JP2008537777A (en) *	2005-03-23	2008-09-25	ワイス	Detection of immune response to GDF-8 modulator
CA2604222A1 (en)	2005-04-18	2006-10-26	Novo Nordisk A/S	Il-21 variants
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
PL1874821T3 (en)	2005-04-26	2013-09-30	Trion Pharma Gmbh	Combination of antibodies and glucocorticoids for treating cancer
WO2007052154A2 (en)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP1885755A4 (en)	2005-05-05	2009-07-29	Univ Duke	TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
WO2007149067A2 (en) *	2005-05-12	2007-12-27	Zymogenetics, Inc.	Methods of using phhla2 to co-stimulate t-cells
CA2611861C (en)	2005-06-08	2017-11-28	The Brigham And Women's Hospital, Inc.	Methods and compositions for the treatment of persistent infections
WO2007014167A2 (en) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
PL2573114T3 (en)	2005-08-10	2016-10-31		Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
WO2007022799A1 (en) *	2005-08-26	2007-03-01	Ares Trading S.A.	Process for the preparation of glycosylated interferon beta
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
JP2009509535A (en) *	2005-09-27	2009-03-12	アムニクス，インコーポレイテッド	Proteinaceous drugs and their use
US20080274096A1 (en) *	2005-10-03	2008-11-06	Astrazeneca Ab	Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
US20090304687A1 (en) *	2005-12-09	2009-12-10	Seattle Genetics , Inc.	Methods of using cd40 binding agents
EP1960419B1 (en) *	2005-12-09	2016-03-16	Ares Trading S.A.	Method for purifying fsh or a fsh mutant
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101384623B (en) *	2005-12-22	2013-07-24	常山凯捷健生物药物研发（河北）有限公司	Preparation method of preformed conjugate of albumin and therapeutic agent
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
WO2007082154A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
CA2637600A1 (en)	2006-01-17	2007-07-26	Health Research, Inc.	Heteroduplex tracking assay
EP1816201A1 (en)	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
US20070248646A1 (en) *	2006-02-16	2007-10-25	Ali Hafezi-Moghadam	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP1999148B8 (en)	2006-03-06	2014-03-05	Medlmmune, LLC	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN102887955A (en)	2006-04-05	2013-01-23	艾博特生物技术有限公司	Purified antibody composition
DE602007007923D1 (en)	2006-04-11	2010-09-02	Csl Behring Gmbh	METHOD FOR INCREASING THE IN VIVO RECOVERY OF THERAPEUTIC POLYPEPTIDES
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
WO2007146038A2 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP2032607B2 (en)	2006-06-14	2017-02-22	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en)	2006-06-14	2007-12-19	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP2049560B1 (en) *	2006-07-13	2013-05-15	Novozymes Biopharma DK A/S	Process for preparing particles of proteinaceous material
CN101511868B (en)	2006-07-24	2013-03-06	比奥雷克西斯制药公司	Exendin fusion proteins
US20090208480A1 (en) *	2006-08-04	2009-08-20	Yue Huang	Long half-life recombinant butyrylcholinesterase
CA2663047A1 (en) *	2006-09-06	2008-03-13	Phase Bioscience, Inc.	Therapeutic elastin-like polypeptide (elp) fusion proteins
CN106008699A (en)	2006-09-08	2016-10-12	Ambrx公司	Modified human plasma polypeptide or Fc scaffolds and their uses
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
PE20081140A1 (en) *	2006-10-25	2008-09-22	Amgen Inc	THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
JP2010507382A (en)	2006-10-26	2010-03-11	ノヴォノルディスクアクティーゼルスカブ	IL-21 mutant
WO2008057459A2 (en)	2006-11-07	2008-05-15	Merck & Co., Inc.	Antagonists of pcsk9
MX2009006398A (en)	2006-12-12	2009-06-23	Biorexis Pharmaceutical Corp	Transferrin fusion protein libraries.
CA2673331A1 (en)	2006-12-19	2008-06-26	Ablynx N.V.	Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (en)	2006-12-19	2009-09-23	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
CA2673459C (en) *	2006-12-22	2016-09-13	Stefan Schulte	Modified coagulation factors with prolonged in vivo half-life
EP2450368A1 (en)	2007-01-30	2012-05-09	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
CA2678001C (en)	2007-02-12	2017-07-11	Stefan Schulte	Therapeutic application of kazal-type serine protease inhibitors
WO2008118386A2 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
AU2008247382B2 (en)	2007-05-07	2014-06-05	Medimmune, Llc	Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MX376656B (en)	2007-05-14	2025-03-07	Kyowa Kirin Co Ltd	METHODS TO REDUCE BASOPHIL LEVELS.
EP2162540A2 (en)	2007-05-22	2010-03-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
CN101784564B (en)	2007-07-13	2014-07-02	约翰霍普金斯大学	B7-DC variants
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
JP2010536341A (en) *	2007-08-15	2010-12-02	アムニクス，インコーポレイテッド	Compositions and methods for altering properties of biologically active polypeptides
MX338397B (en)	2007-08-29	2016-04-15	Sanofi Aventis	Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
JP2009055838A (en) *	2007-08-31	2009-03-19	Nipro Corp	Fusion protein, gene related to fusion protein, vector, transformant and anti-inflammatory pharmaceutical composition
CN101868246A (en) *	2007-09-21	2010-10-20	加利福尼亚大学董事会	Targeted interferons exhibit potent apoptotic and antitumor activity
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
WO2009053360A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
US20100249381A1 (en) *	2007-10-22	2010-09-30	David Delvaille	Method for Purifying FC-Fusion Proteins
WO2009070642A1 (en)	2007-11-28	2009-06-04	Medimmune, Llc	Protein formulation
KR101759457B1 (en)	2007-12-21	2017-07-31	메디뮨 리미티드	BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Rα)-173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009097318A1 (en) *	2008-01-28	2009-08-06	Bristol-Myers Squibb Company	A fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
JP5020135B2 (en) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	Portable terminal device and computer program
CN102065903B (en)	2008-04-01	2015-02-18	诺沃-诺迪斯克有限公司	Insulin albumin conjugates
JP2011516520A (en)	2008-04-07	2011-05-26	アブリンクスエン．ヴェー．	Amino acid sequence having directivity in Notch pathway and use thereof
EA201001734A1 (en)	2008-05-02	2011-10-31	Новартис Аг	IMPROVED BINDING MOLECULES BASED ON FIBRONECTIN AND THEIR APPLICATION
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
PL2291523T3 (en) *	2008-06-24	2015-05-29	Csl Behring Gmbh	Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
CN102131516B (en)	2008-06-27	2016-03-16	杜克大学	Therapeutics comprising elastin-like peptides
CN102149379A (en)	2008-07-10	2011-08-10	安吉翁生物医药有限公司	Methods of modulating hepatocyte growth factor (scatter factor) activity and small molecule modulator compositions of hepatocyte growth factor (scatter factor) activity
WO2010010119A1 (en)	2008-07-22	2010-01-28	Ablynx Nv	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
PY09026846A (en)	2008-08-05	2015-09-01	Novartis Ag	COMPOSITIONS AND METHODS FOR ANTIBODIES THAT TARGET THE C5 COMPLEMENT PROTEIN
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
JP2012500855A (en) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	PD-1 antagonists and methods for treating infectious diseases
NZ591488A (en)	2008-09-07	2012-11-30	Glyconex Inc	Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP5933975B2 (en)	2008-11-12	2016-06-15	メディミューン，エルエルシー	Antibody preparation
WO2010059315A1 (en)	2008-11-18	2010-05-27	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
MX2011005691A (en)	2008-11-28	2011-07-20	Univ Emory	Methods for the treatment of infections and tumors.
EP3255060A1 (en) *	2008-12-09	2017-12-13	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
US8637454B2 (en)	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN102378635A (en)	2009-01-16	2012-03-14	特瓦制药工业有限公司	Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8703717B2 (en) *	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
ES2610356T3 (en)	2009-02-03	2017-04-27	Amunix Operating Inc.	Extended recombinant polypeptides and compositions comprising the same
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
KR101722961B1 (en)	2009-02-11	2017-04-04	알부메딕스 에이/에스	Albumin variants and conjugates
CA2755336C (en)	2009-03-20	2015-07-14	Amgen Inc.	Carrier immunoglobulins and uses thereof
DK2427486T3 (en)	2009-05-07	2015-05-26	Novozymes Biopharma Dk As	A process for purifying albumin
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
US11512326B2 (en) *	2009-05-26	2022-11-29	University Of Florida Research Foundation, Incorporated	Small angiotensin peptide expression system in mammalian cells
WO2010144508A1 (en) *	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CA2769822C (en)	2009-08-13	2019-02-19	The Johns Hopkins University	Methods of modulating immune function
WO2011020866A2 (en)	2009-08-20	2011-02-24	Csl Behring Gmbh	Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
CA2771999A1 (en)	2009-08-24	2011-03-10	Amunix Operating Inc.	Coagulation factor vii compositions and methods of making and using same
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US12544491B2 (en)	2009-08-24	2026-02-10	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (en)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	DLL-4 BINDING MOLECULES
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
JP5898082B2 (en)	2009-10-07	2016-04-06	マクロジェニクス，インコーポレーテッド	Fc region-containing polypeptide exhibiting improved effector function by changing the degree of fucosylation and use thereof
WO2011051278A1 (en) *	2009-10-26	2011-05-05	Externautics S.P.A.	Lung tumor markers and methods of use thereof
IN2012DN03824A (en)	2009-10-30	2015-08-28	Merck Sharp & Dohme
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
EP2493921B1 (en)	2009-10-30	2018-09-26	Albumedix Ltd	Albumin variants
CN102596249A (en)	2009-10-30	2012-07-18	默沙东公司	AX1 and AX189 PCSK9 antagonists and variants
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
CA2817671A1 (en) *	2009-11-17	2011-05-26	Universite De Montreal	Heteropeptides useful for reducing nonspecific adsorption
SI2506868T1 (en) *	2009-12-06	2018-04-30	Bioverativ Therapeutics Inc.	Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JP2013512959A (en)	2009-12-08	2013-04-18	テバファーマシューティカルインダストリーズリミティド	BChE albumin fusion for treating cocaine abuse
EP3309176B1 (en)	2009-12-14	2025-10-01	Ablynx N.V.	Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
CA2784861A1 (en)	2009-12-21	2011-07-14	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
SMT201800552T1 (en)	2010-01-06	2018-11-09	Dyax Corp	Plasma kallikrein binding proteins
AR079944A1 (en)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
MX338357B (en)	2010-01-22	2016-04-13	Novo Nordisk Healthcare Ag	Stable growth hormone compounds.
RS59459B1 (en)	2010-01-22	2019-11-29	Novo Nordisk Healthcare Ag	Growth hormones with prolonged in-vivo efficacy
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP2547328B1 (en) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Ccr7 ligand delivery and co-delivery in immunotherapy
NZ601117A (en)	2010-03-03	2014-06-27	Boehringer Ingelheim Int	Biparatopic abeta binding polypeptides
EP2371857A1 (en)	2010-04-01	2011-10-05	CSL Behring GmbH	Factor XII inhibitors for treating interstitial lung disease
EP2556087A1 (en)	2010-04-09	2013-02-13	Novozymes Biopharma DK A/S	Albumin derivatives and variants
PH12012502193A1 (en)	2010-05-06	2021-08-09	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en)	2010-05-06	2017-12-20	Novartis AG	Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
EP2571901B1 (en)	2010-05-20	2019-01-02	Ablynx N.V.	Biological materials related to her3
PL3552619T3 (en)	2010-07-09	2025-12-01	Bioverativ Therapeutics Inc.	Factor ix polypeptides and methods of use thereof
EP3508573A1 (en)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2013121296A1 (en)	2012-02-15	2013-08-22	Ecole Polytechnique Federale De Lausanne	Erythrocyte-binding therapeutics
EP2603520A4 (en)	2010-08-10	2014-02-19	Ecole Polytech	THERAPEUTIC AGENTS BINDING TO ERYTHROCYTES
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
AU2011290672B2 (en)	2010-08-20	2015-07-09	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
AU2011295715B9 (en)	2010-09-03	2017-02-23	Abbvie Stemcentrx Llc	Novel modulators and methods of use
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
MX360946B (en)	2010-09-22	2018-10-29	Amgen Inc Star	CARRYING IMMUNOGLOBULINS AND USES OF THE SAME.
PT2621515T (en)	2010-09-28	2017-07-12	Aegerion Pharmaceuticals Inc	A chimeric seal-human leptin polypeptide with increased solubility
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
US20130225496A1 (en)	2010-11-01	2013-08-29	Novozymes Biopharma Dk A/S	Albumin Variants
ES2758994T3 (en)	2010-11-05	2020-05-07	Zymeworks Inc	Stable heterodimeric antibody design with mutations in the Fc domain
AU2011328246B2 (en)	2010-11-08	2016-06-30	Ablynx N.V.	CXCR2 binding polypeptides
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
NZ611428A (en)	2010-12-08	2015-07-31	Stemcentrx Inc	Novel modulators and methods of use
EP2660600B1 (en)	2010-12-28	2018-08-08	Sumitomo Dainippon Pharma Co., Ltd.	Diagnostic drug and diagnostic method for alzheimer's disease
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102320178B1 (en)	2011-01-06	2021-11-02	다케다 파머수티컬 컴패니 리미티드	Plasma kallikrein binding proteins
SA112330278B1 (en)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	Novel modulators and methods of use
CA2828405A1 (en)	2011-02-28	2012-09-07	Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale	Apoptosis-inducing molecules and uses therefor
AU2012222833B2 (en)	2011-03-03	2017-03-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9352016B2 (en)	2011-03-09	2016-05-31	Csl Behring Gmbh	Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
TWI719112B (en)	2011-03-16	2021-02-21	賽諾菲公司	Uses of a dual v region antibody-like protein
PH12013501865A1 (en)	2011-03-16	2014-01-06	Amgen Inc	Potent and selective inhibitors of nav1.3 and nav1.7
US9340584B2 (en)	2011-03-29	2016-05-17	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
PE20140964A1 (en)	2011-03-30	2014-08-17	Boehringer Ingelheim Int	ANTICOAGULANT ANTIDOTES
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
NZ713461A (en)	2011-04-15	2017-02-24	Compugen Ltd	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) *	2011-04-22	2015-08-12	Sysmex Corporation	Method for electrochemically detecting analyte
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (en)	2011-05-05	2018-07-10	Мерк Патент Гмбх	POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
CA2830660A1 (en)	2011-05-05	2012-11-08	Novozymes Biopharma Dk A/S	Albumin variants
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
US9486507B2 (en)	2011-06-10	2016-11-08	Biogen Ma Inc.	Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR102231139B1 (en) *	2011-06-28	2021-03-24	인히브릭스, 인크.	Serpin fusion polypeptides and methods of use thereof
RU2014103288A (en)	2011-07-01	2015-08-10	Байер Интеллектчуал Проперти Гмбх	RELAXIN FUSED POLYPEPTIDES AND THEIR APPLICATION
JP6247210B2 (en)	2011-07-05	2017-12-13	アルブミディクスアクティーゼルスカブ	Albumin preparation and use
KR20140039257A (en)	2011-07-08	2014-04-01	바이엘 인텔렉쳐 프로퍼티 게엠베하	Fusion proteins releasing relaxin and uses thereof
CN103957926B (en)	2011-07-08	2018-07-03	安米林药品有限责任公司	Engineered polypeptides with enhanced duration of action and reduced immunogenicity
BR112014001274A2 (en) *	2011-07-18	2017-04-18	Arts Biologics As	luteinizing hormone compound and pharmaceutical composition
IL230564B2 (en)	2011-07-22	2023-09-01	Csl Ltd	Inhibitory anti-factor xii/xiia monoclonal antibodies, methods of producing the same, pharmaceutical compositions containing the same and medical uses
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19216461T1 (en)	2011-10-03	2021-10-07	Modernatx, Inc.	MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USES THEREOF
US10598653B2 (en)	2011-11-01	2020-03-24	Bionomics Inc.	Methods of blocking cancer stem cell growth
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
WO2013067057A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
CN104053671A (en)	2011-11-01	2014-09-17	生态学有限公司	Antibodies and methods of treating cancer
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
ES2666856T3 (en)	2011-11-04	2018-05-08	Novartis Ag	Protein 6 related to low density lipoproteins (LRP6) - half-life extender constructs
BR112014010580B1 (en)	2011-11-04	2021-01-12	Zymeworks, Inc.	isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct
EP2780364A2 (en)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
EP3590538A1 (en)	2011-12-05	2020-01-08	Novartis AG	Antibodies for epidermal growth factor receptor 3 (her3)
CN104105709A (en)	2011-12-05	2014-10-15	诺华股份有限公司	Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
ES2728278T3 (en)	2011-12-21	2019-10-23	Novartis Ag	Compositions comprising antibodies directed to factor P and C5
JP6127063B2 (en)	2011-12-22	2017-05-10	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Use of C1 inhibitors for the treatment of secondary edema of the central nervous system
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
CN104271150A (en)	2012-01-12	2015-01-07	比奥根艾迪克Ma公司	Chimeric factor viii polypeptides and uses thereof
EP2623110A1 (en)	2012-01-31	2013-08-07	CSL Behring GmbH	Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2013120939A1 (en) *	2012-02-15	2013-08-22	Csl Behring Gmbh	Von willebrand factor variants having improved factor viii binding affinity
EP2822577B1 (en)	2012-02-15	2019-02-06	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
JP6256882B2 (en)	2012-02-15	2018-01-10	アムニクスオペレーティングインコーポレイテッド	Factor VIII composition, and method of making and use of the composition
BR112014020826A8 (en)	2012-02-24	2017-09-19	Stem Centrx Inc	ANTIBODY SPECIFICALLY BINDING TO AN Epitope, NUCLEIC ACID, VECTOR OR HOST CELL, DRUG CONJUGATE ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY, USE THEREOF, KIT AND METHOD OF PREPARATION OF THE CONJUGATE
PH12021553014A1 (en)	2012-02-27	2022-09-05	Ablynx Nv	Cx3cr1-binding polypeptides
DK2825556T3 (en)	2012-03-16	2018-04-16	Albumedix As	albumin Variants
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
CA2862516C (en)	2012-03-27	2023-02-14	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
CN110078827A (en) *	2012-04-27	2019-08-02	西托姆克斯治疗公司	In conjunction with its application method of the activable antibody of EGF-R ELISA
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
AU2013258834B2 (en)	2012-05-10	2017-09-07	Zymeworks Bc Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
EP2854535A1 (en)	2012-05-30	2015-04-08	Bayer Cropscience AG	Compositions comprising a biological control agent and an insecticide
EP3281526A1 (en)	2012-05-30	2018-02-14	Bayer CropScience Aktiengesellschaft	Composition comprising a biological control agent and a fungicide
NZ725994A (en)	2012-05-30	2018-07-27	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis
CN107027809A (en)	2012-05-30	2017-08-11	拜耳作物科学股份公司	The composition of fungicide comprising biocontrol agent and selected from Respiratory Chain Complex I or II inhibitor
WO2013178661A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositiions comprising a biological control agent and an insecticide
PT2854552T (en)	2012-05-30	2019-07-25	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of atp production and inhibitors of the cell wall synthesis
WO2013178658A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
KR20150023475A (en)	2012-05-30	2015-03-05	바이엘 크롭사이언스 아게	Composition comprising a biological control agent and a fungicide selected from inhibitors of the lipid membrane synthesis, the melanine biosynthesis, the nucleic acid synthesis or the signal transduction
AU2013269662B2 (en)	2012-05-30	2016-12-15	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
HRP20181752T1 (en)	2012-05-30	2018-12-28	Bayer Cropscience Ag	Composition comprising a biological control agent and fluopicolide
EP2854529B1 (en)	2012-05-30	2018-01-17	Bayer Cropscience AG	Compositions comprising a biological control agent and an insecticide
TR201816257T4 (en)	2012-05-30	2018-11-21	Bayer Cropscience Ag	Composition comprising a biological control agent and trifloxystrobin.
CA2875247A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Chimeric clotting factors
WO2013185113A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Procoagulant compounds
KR101380740B1 (en)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	Purification of iduronate-2-sulfatase
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN104661674A (en)	2012-07-11	2015-05-27	阿穆尼克斯运营公司	Factor VIII complexes with XTEN and von Willebrand Factor protein, and uses thereof
WO2014012082A2 (en)	2012-07-13	2014-01-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design an constructs
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
HK1211981A1 (en)	2012-09-02	2016-06-03	Abbvie Inc.	Methods to control protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1213767A1 (en)	2012-10-18	2016-07-15	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
MX2015005363A (en)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Albumin variants.
JP6499079B2 (en)	2012-11-13	2019-04-10	バイオエヌテックアーゲーＢｉｏＮＴｅｃｈＡＧ	Agents for treating cancer diseases that express claudin
PL2922554T3 (en)	2012-11-26	2022-06-20	Modernatx, Inc.	Terminally modified rna
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
DK2928921T3 (en)	2012-12-05	2021-04-19	Novartis Ag	COMPOSITIONS AND PROCEDURES FOR ANTIBODIES TARGETED EPO
US20160067347A1 (en)	2012-12-20	2016-03-10	Amgen Inc.	Apj receptor agonists and uses thereof
EP2945703A4 (en)	2013-01-15	2016-08-31	Teva Pharma	Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (en) *	2013-01-17	2015-03-20	서울대학교산학협력단	Recombinant protein vaccine for preventing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae infection diseases
KR101993714B1 (en)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
TWI635098B (en)	2013-02-01	2018-09-11	再生元醫藥公司	Antibody containing chimeric constant region
MX2015010259A (en)	2013-02-11	2015-10-29	Bayer Cropscience Lp	Compositions comprising a streptomyces-based biological control agent and another biological control agent.
WO2014127215A1 (en)	2013-02-15	2014-08-21	Biogen Idec Ma Inc.	Optimized factor viii gene
US20160033523A1 (en)	2013-02-16	2016-02-04	Novozymes Biopharma Dk A/S	Pharmacokinetic animal model
ES2609070T3 (en)	2013-02-28	2017-04-18	Csl Behring Gmbh	Therapeutic agent for amniotic fluid embolism
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
CN105188750A (en)	2013-03-08	2015-12-23	德国杰特贝林生物制品有限公司	Treatment and prevention of remote ischemia-reperfusion injury
WO2014164703A1 (en)	2013-03-11	2014-10-09	University Of Florida Research Foundation, Inc.	Delivery of card protein as therapy for occular inflammation
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165277A2 (en)	2013-03-12	2014-10-09	Amgen Inc.	POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP2968587A2 (en)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP2968391A1 (en) *	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP3611189A1 (en)	2013-03-14	2020-02-19	Novartis AG	Antibodies against notch 3
WO2014144549A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Factor ix polypeptide formulations
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2978451B1 (en)	2013-03-29	2019-11-27	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
EP2796145B1 (en)	2013-04-22	2017-11-01	CSL Ltd.	A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
UY35620A (en)	2013-06-21	2015-01-30	Novartis Ag	ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
AR096601A1 (en)	2013-06-21	2016-01-20	Novartis Ag	ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
CN113817069A (en)	2013-06-28	2021-12-21	比奥贝拉蒂治疗公司	Thrombin cleavable linker with XTEN and uses thereof
CA2916399C (en)	2013-06-28	2022-08-02	Marc Nolte	Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN104342420B (en) *	2013-07-30	2017-09-15	惠觅宙	A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application
TW202003554A (en)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	Factor VIII-XTEN fusions and uses thereof
US20160311885A1 (en)	2013-08-14	2016-10-27	Biogen Ma Inc.	Recombinant factor viii proteins
CA2920835A1 (en)	2013-08-20	2015-02-26	Anutra Medical, Inc.	Syringe fill system and method
SG11201601424PA (en)	2013-08-28	2016-03-30	Stemcentrx Inc	Site-specific antibody conjugation methods and compositions
CN105792836A (en)	2013-08-28	2016-07-20	施特姆森特克斯股份有限公司	Novel SEZ6 modulators and methods of use
HUE057005T2 (en)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Column virus inactivation procedures
CN103468662A (en) *	2013-09-29	2013-12-25	惠觅宙	Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
ES2714708T3 (en)	2013-10-01	2019-05-29	Mayo Found Medical Education & Res	Procedures for the treatment of cancer in patients with elevated levels of Bim
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions and methods for treatment of inflammatory bowel disease
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
WO2015066279A2 (en)	2013-10-30	2015-05-07	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
HRP20192080T1 (en)	2013-10-31	2020-02-07	Resolve Therapeutics, Llc	THERAPEUTIC NUCLEASE-ALBUMINE FUSIONS AND PROCEDURES
KR101977449B1 (en)	2013-11-01	2019-05-10	유니버시티에트 이 오슬로	Albumin variants and uses thereof
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015089283A1 (en)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015104711A1 (en)	2014-01-09	2015-07-16	Hadasit Medical Research Services And Development Ltd.	Improved cell compositions and methods for cancer therapy
AU2015204646B2 (en)	2014-01-10	2020-08-27	Bioverativ Therapeutics Inc.	Factor VIII chimeric proteins and uses thereof
SG11201606761RA (en)	2014-02-21	2016-09-29	Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
AU2015229381B2 (en)	2014-03-11	2019-11-07	University Of Florida Research Foundation, Inc.	Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
WO2015140591A1 (en)	2014-03-21	2015-09-24	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
CA2947127A1 (en)	2014-05-02	2015-11-19	Cerenis Therapeutics Holding Sa	Hdl therapy markers
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (en) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	Fusion protein and its preparation method and use
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
WO2015191781A2 (en)	2014-06-10	2015-12-17	Amgen Inc.	Apelin polypeptides
JP7109160B2 (en)	2014-06-18	2022-07-29	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Therapy using factor XII inhibitors in neurotraumatic disorders
EP3157947A1 (en)	2014-06-23	2017-04-26	Novartis AG	Hsa-gdf-15 fusion polypeptide and use thereof
RU2017101436A (en)	2014-06-24	2018-07-24	Ново Нордиск А/С	MIC-1 FUSION PROTEINS AND THEIR APPLICATION
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
AU2015296640B2 (en)	2014-07-30	2020-05-21	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
WO2016020880A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
JP6886917B2 (en)	2014-08-22	2021-06-16	國立成功大學ＮａｔｉｏｎａｌＣｈｅｎｇＫｕｎｇＵｎｉｖｅｒｓｉｔｙ	A lodestone variant, a polynucleotide encoding a lodestone variant, a recombinant host cell containing the polynucleotide, and a pharmaceutical composition comprising the lodestone variant.
MX390380B (en)	2014-09-17	2025-03-20	Basf Corp	COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT.
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CU20170038A7 (en)	2014-09-26	2017-10-05	Bayer Pharma AG	DERIVATIVES OF ADRENOMEDULIN STABILIZED ESPECIALLY USEFUL IN THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR, EDEMATOS AND / OR INFLAMMATORY DISORDERS
MA41044A (en)	2014-10-08	2017-08-15	Novartis Ag	COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
BR112017007765B1 (en)	2014-10-14	2023-10-03	Halozyme, Inc	COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
MA40835A (en)	2014-10-23	2017-08-29	Biogen Ma Inc	ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en)	2014-10-31	2017-09-05	Biogen Ma Inc	ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
EP3701969A1 (en)	2014-10-31	2020-09-02	NGM Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (en)	2014-12-19	2016-07-29	Novartis Ag	COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
EP3590500B1 (en)	2014-12-23	2025-06-25	Merz Pharma GmbH & Co. KGaA	Botulinum toxin prefilled container
WO2016161010A2 (en) *	2015-03-30	2016-10-06	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to fc gamma receptors
JP2016204292A (en) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Fusion of BMP7 mutant and albumin, and renal disease therapeutic agent containing the fusion
JP2018518945A (en) *	2015-04-29	2018-07-19	メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ	Soluble chimeric interleukin-10 receptor and therapeutic use thereof
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (en) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Methods of treatment for conditions mediated by substance p
EP3303387A2 (en)	2015-06-05	2018-04-11	Novartis AG	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
JP2018524067A (en)	2015-06-11	2018-08-30	アットウィルメディカルソルーションズインコーポレイテッド	Medical devices, systems and methods utilizing antithrombin-heparin compositions
UY36751A (en)	2015-06-26	2017-01-31	Novartis Ag	FACTOR XI ANTIBODIES AND METHODS OF USE
US11020455B2 (en) *	2015-07-30	2021-06-01	Endor Technologies, S.L	Colony stimulating factor for use in pancreatic or colon cancer treatment
US11236159B2 (en)	2015-08-03	2022-02-01	Novartis Ag	Methods of treating FGF21-associated disorders
EA201890423A1 (en)	2015-08-03	2018-07-31	Биовератив Терапьютикс Инк.	SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
WO2017024198A1 (en) *	2015-08-06	2017-02-09	The Trustees Of The University Of Pennsylvania	Glp-1 and use thereof in compositions for treating metabolic diseases
JP7007261B2 (en)	2015-08-20	2022-01-24	アルブミディクスリミティド	Albumin variants and conjugates
CA3183289A1 (en)	2015-09-08	2017-03-16	Jcr Pharmaceuticals Co., Ltd.	Novel human serum albumin mutant
EA038332B1 (en)	2015-09-09	2021-08-10	Новартис Аг	Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
HRP20210650T1 (en)	2015-09-09	2021-05-28	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
CN117659160A (en) *	2015-09-11	2024-03-08	小利兰·斯坦福大学托管委员会	Orthogonal cytokine/receptor pairs of biological relevance
AU2016325630B2 (en)	2015-09-23	2022-11-17	Regeneron Pharmaceuticals, Inc.	Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
UA122079C2 (en)	2015-12-04	2020-09-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	POLYPEPTIDE SPECIFICALLY BINDED TO LRP5 AND LRP6
EP3387018A1 (en)	2015-12-11	2018-10-17	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
RU2018126297A (en)	2015-12-18	2020-01-22	Новартис Аг	ANTIBODIES AIMED AT CD32B AND WAYS TO USE THEM
JP6946304B2 (en)	2015-12-22	2021-10-06	ノバルティスアーゲー	Methods of Treating or Relieving Metabolic Disorders Using Proliferative Differentiation Factor 15 (GDF-15)
WO2017122130A1 (en)	2016-01-11	2017-07-20	Novartis Ag	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
MA55746A (en)	2016-01-21	2022-03-02	Novartis Ag	MULTISPECIFIC MOLECULES TARGETING CLL-1
CA3012695A1 (en)	2016-02-01	2017-08-10	Bioverativ Therapeutics Inc.	Optimized factor viii genes
JP2017165713A (en)	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	Serum albumin-20K growth hormone fusion protein
WO2017161414A1 (en)	2016-03-22	2017-09-28	Bionomics Limited	Administration of an anti-lgr5 monoclonal antibody
MY194669A (en)	2016-03-31	2022-12-12	Ngm Biopharmaceuticals Inc	Binding Proteins and Methods of use Thereof
US11174321B2 (en)	2016-04-06	2021-11-16	Csl Limited	Method of treating atherosclerosis
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
RS61510B1 (en)	2016-05-18	2021-03-31	Boehringer Ingelheim Int	Anti pd-1 and anti-lag3 antibodies for cancer treatment
KR102433503B1 (en)	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	MIC-1 compounds and their use
AU2017283787B2 (en)	2016-06-15	2020-09-17	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
EP3481416B1 (en) *	2016-07-08	2020-09-09	CSL Behring Lengnau AG	Subcutaneous administration of long-acting factor ix in humans
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en)	2016-08-23	2019-06-20	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
EP3535585A1 (en)	2016-11-04	2019-09-11	Aarhus Universitet	Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
JP2019535834A (en) *	2016-11-18	2019-12-12	ユニベルシタデバルセロナ	CD6 and imipenem combination therapy for the treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
MX2019006444A (en)	2016-12-02	2019-10-30	Bioverativ Therapeutics Inc	HEMOPHILIC ARTHROPATHY TREATMENT METHODS USING CHEMERIC COAGULATION FACTORS.
JP2019536794A (en)	2016-12-02	2019-12-19	バイオベラティブセラピューティクスインコーポレイテッド	Methods for inducing immune tolerance to coagulation factors
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US20200031895A1 (en)	2016-12-16	2020-01-30	Biogen Ma Inc.	Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
IL267519B2 (en)	2016-12-23	2025-04-01	Novartis Ag	Factor XI/XIA FOR USE IN PREVENTING, TREATING, MANAGING OR REDUCING THE RISK OF STROKE OR THROMBOEMBOLISM IN A SUBJECT AFFLICTED WITH END STAGE RENAL DISEASE
AU2017383232B2 (en)	2016-12-23	2024-09-12	Novartis Ag	Factor XI antibodies and methods of use
KR20230125856A (en)	2016-12-23	2023-08-29	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	Gene editing of pcsk9
WO2018132768A1 (en)	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
EA201991768A1 (en)	2017-01-31	2020-01-22	Байоверетив Терапьютикс Инк.	FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
KR102572663B1 (en)	2017-02-08	2023-09-01	노파르티스 아게	FGF21 Mimetic Antibodies and Uses Thereof
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020517657A (en)	2017-04-20	2020-06-18	ノヴォノルディスクアー／エス	Purification method of albumin fusion protein
TWI710377B (en)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Mic-1 compounds and uses thereof
MY206158A (en)	2017-05-24	2024-12-02	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630816B1 (en)	2017-05-31	2024-03-20	Boehringer Ingelheim International GmbH	Polypeptides antagonizing wnt signaling in tumor cells
WO2018232176A1 (en)	2017-06-16	2018-12-20	The University Of Chicago	Compositions and methods for inducing immune tolerance
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018294517B2 (en)	2017-06-29	2024-09-26	CSL Behring Lengnau AG	21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof
LT3661562T (en)	2017-08-04	2024-10-25	Amgen Inc.	METHOD OF CONJUGATION OF CYS-MAB
NZ762100A (en)	2017-08-09	2025-12-19	Bioverativ Therapeutics Inc	Nucleic acid molecules and uses thereof
EP3684811A2 (en)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
IL273185B2 (en)	2017-09-15	2024-10-01	Cedars Sinai Medical Center	C1 esterase inhibitors for use in improving tissue function in uterine transplantation in patients
JP7793287B2 (en) *	2017-10-18	2026-01-05	シーエスエルリミティド	Human serum albumin variants and uses thereof
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
AU2018382222B2 (en)	2017-12-15	2025-09-04	Csl Limited	Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (en)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Triabody, preparation method and use thereof
CN117050184A (en)	2017-12-28	2023-11-14	南京传奇生物科技有限公司	Single domain antibodies to TIGIT and variants thereof
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
CN111699200B (en)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	Single domain antibodies against PD-1 and variants thereof
AU2019215063B2 (en)	2018-02-01	2025-10-16	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing Factor VIII
ES2953362T3 (en) *	2018-03-13	2023-11-10	Sepsia Therapeutics S L	Bacterial binding peptides for the treatment of infectious diseases and related inflammatory processes
IL277049B2 (en)	2018-03-13	2024-02-01	Zymeworks Bc Inc	Anti-her2 biparatopic antibody-drug conjugates and methods of use
PE20210313A1 (en)	2018-03-28	2021-02-12	Bristol Myers Squibb Co	INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
TW202003567A (en)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	Single-domain antibodies against LAG-3 and uses thereof
KR102119197B1 (en) *	2018-04-23	2020-06-05	주식회사 엘베이스	Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same
EP3790577A4 (en)	2018-05-09	2022-04-27	The University of Chicago	COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
WO2019222296A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en)	2018-05-14	2025-05-29	Werewolf Therapeutics, Inc.	Activatable interleukin-2 polypeptides and methods of use thereof
PL3793588T3 (en)	2018-05-18	2025-09-01	Bioverativ Therapeutics Inc.	Methods of treating hemophilia a
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
TWI869346B (en)	2018-05-30	2025-01-11	瑞士商諾華公司	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
KR102870868B1 (en)	2018-06-01	2025-10-15	노파르티스 아게	Binding molecules for BCMA and uses thereof
EP3806889A4 (en)	2018-06-18	2022-07-13	Anwita Biosciences, Inc.	CYTOKINE-BASED FUSION PROTEINS AND THEIR USES
KR20210027426A (en)	2018-07-03	2021-03-10	브리스톨-마이어스 스큅 컴퍼니	FGF21 formulation
EP3833766A1 (en)	2018-08-09	2021-06-16	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
CA3110513A1 (en)	2018-08-31	2020-03-05	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
EP3852874A1 (en) *	2018-09-17	2021-07-28	Kyoto University	Administration of an anti-c5 agent for treatment of hepatic injury or failure
US20220002370A1 (en)	2018-09-27	2022-01-06	Xilio Development, Inc.	Masked cytokine polypeptides
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (en)	2018-10-15	2020-05-29	Novartis Ag	TREM2 STABILIZING ANTIBODIES
CA3117961A1 (en) *	2018-10-29	2020-05-07	Spin Therapeutics, Llc	Compositions and methods for alpha-1-antitrypsin disorders
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
EP3887393A1 (en)	2018-11-26	2021-10-06	Novartis AG	Lpl-gpihbp1 fusion polypeptides
JP7644007B2 (en)	2018-12-06	2025-03-11	バイオベラティブセラピューティクスインコーポレイテッド	Use of lentiviral vectors expressing factor IX
US20230051872A1 (en)	2019-03-22	2023-02-16	Reflexion Pharmaceuticals, Inc.	Multivalent D-Peptidic Compounds for Target Proteins
KR20220044612A (en)	2019-03-22	2022-04-08	리플렉시온 파마슈티컬스, 인크.	D-peptidic compounds for vegf
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
EP3927702A4 (en)	2019-04-11	2022-05-11	Angion Biomedica Corp.	Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
EP3969035A4 (en)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	SEPARATION CHARACTERISTIC GROUPS, ASSOCIATED PROCESSES AND USE
US12037378B2 (en)	2019-05-21	2024-07-16	Novartis Ag	Variant CD58 domains and uses thereof
JP7489407B2 (en)	2019-05-21	2024-05-23	ノバルティスアーゲー	CD19 binding molecules and uses thereof
JP7784898B2 (en)	2019-05-24	2025-12-12	サノフイ	Methods for treating systemic sclerosis
EP3986918A1 (en)	2019-06-18	2022-04-27	Bayer Aktiengesellschaft	Adrenomedullin-analogues for long-term stabilization and their use
IL267614A (en)	2019-06-24	2019-09-26	Lotem Michal	Nucleic acid agents modulating slamf6 isoforms
MX2022002638A (en)	2019-09-06	2022-03-25	Novartis Ag	Therapeutic fusion proteins.
CN114502590A (en)	2019-09-18	2022-05-13	诺华股份有限公司	ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies
TW202124446A (en)	2019-09-18	2021-07-01	瑞士商諾華公司	Combination therapies with entpd2 antibodies
KR20220097891A (en)	2019-09-30	2022-07-08	바이오버라티브 테라퓨틱스 인크.	Lentiviral vector formulation
US20240228573A9 (en) *	2019-10-17	2024-07-11	Jcr Pharmaceuticals Co., Ltd.	Method for producing fusion protein of serum albumin and growth hormone
WO2021085518A1 (en)	2019-10-30	2021-05-06	Ｊｃｒファーマ株式会社	Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
MX2022005666A (en)	2019-11-14	2022-10-07	Werewolf Therapeutics Inc	ACTIVABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF.
US20230000774A1 (en)	2019-12-04	2023-01-05	Albumedix Limited	Methods and compositions produced thereby
CN121517534A (en)	2019-12-13	2026-02-13	辛德凯因股份有限公司	IL-2 orthogonal homologs and their usage
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
CN115379850A (en)	2019-12-24	2022-11-22	裘美娜治疗公司	Regenerative polypeptide and use thereof
EP4090427A1 (en)	2020-01-13	2022-11-23	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
MX2022012683A (en)	2020-04-09	2023-01-11	Verve Therapeutics Inc	Base editing of pcsk9 and methods of using same for treatment of disease.
WO2021236658A1 (en)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
CA3182800A1 (en)	2020-06-14	2021-12-23	Vertex Pharmaceuticals Inc.	Complement factor i-related compositions and methods
MX2023000156A (en)	2020-06-24	2023-02-16	Bioverativ Therapeutics Inc	METHODS FOR THE ELIMINATION OF FREE FACTOR VIII FROM PREPARATIONS OF LENTIVIRAL VECTORS MODIFIED TO EXPRESS SAID PROTEIN.
EP4232474A1 (en)	2020-10-21	2023-08-30	Boehringer Ingelheim International GmbH	Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
CA3200309A1 (en) *	2020-10-30	2022-05-05	Shenzhen Protgen Ltd.	Use of human serum albumin in treatment of diseases
CA3199095A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
WO2022115865A2 (en)	2020-11-25	2022-06-02	Xilio Development, Inc.	Tumor-specific cleavable linkers
WO2022166720A1 (en) *	2021-02-05	2022-08-11	华南理工大学	Serum albumin-based fusion protein, and nano-assembly, preparation method therefor and application thereof
CN117321076A (en)	2021-02-19	2023-12-29	美国卫生及公众服务部代表	Single domain antibodies that neutralize SARS-CoV-2
JP2024523033A (en)	2021-06-17	2024-06-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Novel trispecific binding molecules
WO2022271466A1 (en) *	2021-06-21	2022-12-29	Juvena Therapeutics, Inc.	Regenerative polypeptides and uses thereof
CN114133458B (en) *	2021-12-08	2023-11-14	福州大学	A method for fusing polypeptides within human serum albumin
CA3250114A1 (en) *	2022-01-28	2023-08-03	Sigilon Therapeutics, Inc.	Therapies for mucopolysaccharidosis type 6
IL316174A (en)	2022-04-26	2024-12-01	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
EP4554619A1 (en)	2022-07-15	2025-05-21	Danisco US Inc.	Methods for producing monoclonal antibodies
IL317689A (en)	2022-07-15	2025-02-01	Boehringer Ingelheim Int	Binding molecules for the treatment of cancer
EP4605077A1 (en)	2022-10-18	2025-08-27	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
JP2026503406A (en) *	2022-12-20	2026-01-29	シーエスエルイノベーションプロプライアタリーリミティド	FcRn antagonists and uses thereof
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations and uses thereof
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
EP4703468A1 (en)	2024-08-29	2026-03-04	Sartorius Albumedix Limited	Methods and uses
WO2026058155A1 (en)	2024-09-11	2026-03-19	Novartis Ag	Antibodies targeting il-31
WO2026074121A1 (en)	2024-10-02	2026-04-09	Sartorius Albumedix Limited	Albumin formulations and uses thereof

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (en) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
ES8308534A1 (en)	1980-01-08	1983-09-01	Biogen Nv	DNA sequences, recombinant DNA molecules and processes for producing human interferon-alpha like polypeptides.
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
EP0041313B1 (en)	1980-04-03	1990-09-12	Biogen, Inc.	Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon
DE3023787A1 (en)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
GR81946B (en)	1980-09-25	1984-12-12	Genentech Inc
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3273787D1 (en)	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en)	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
CA1204682A (en)	1981-06-19	1986-05-20	Saran A. Narang	Adaptors, and synthesis and cloning of proinsulin genes
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (en)	1981-11-12	1984-08-08	The Upjohn Company	Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (en)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	Phase adjusting device for shaker cam in powder molding press
JPS58118008A (en)	1982-01-06	1983-07-13	Nec Corp	Data processor
WO1983002461A1 (en)	1982-01-19	1983-07-21	Cetus Corp	Multiclass hybrid interferons
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
CA1341562C (en)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
DE3377363D1 (en)	1982-03-31	1988-08-18	Ajinomoto Kk	Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (en)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Pharmaceutical compositions for tumour treatment
EP0102324A3 (en)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipids and surfactants in an aqueous medium
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
JPS5945835U (en)	1982-09-16	1984-03-27	株式会社東芝	Arc extinguishing device for circuit breakers and breakers
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
IE56026B1 (en)	1982-10-19	1991-03-27	Cetus Corp	Cysteine-depleted muteins of biologically active proteins
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
EP0116201B1 (en)	1983-01-12	1992-04-22	Chiron Corporation	Secretory expression in eukaryotes
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
DK172738B1 (en)	1983-04-07	1999-06-21	Chiron Corp	Method for expressing mature insulin and DNA structure for use in the method
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
JPS60501140A (en)	1983-04-22	1985-07-25	アムジエン	Secretion of exogenous polypeptides by yeast
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Slow release injectable insulin composition
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (en)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	Variant control region
DE3483949D1 (en)	1983-09-26	1991-02-21	Udo Dr Med Ehrenfeld	AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLED AND HUMORAL IMMUNE DEFENSE.
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
DE3474511D1 (en)	1983-11-01	1988-11-17	Terumo Corp	Pharmaceutical composition containing urokinase
JPS60115528A (en)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	Human interleukin-2 protein, its production and pharmacological composition containing the same
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (en)	1983-12-26	1985-07-20	Suntory Ltd	Peptide and diuretic comprising it as active ingredient
IT1185503B (en)	1984-01-11	1987-11-12	Univ New York	HUMAN Erythropietine ODNA CLONES
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
CA1213537A (en)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Polypeptide expression method
FR2564106B1 (en) *	1984-05-09	1988-04-22	Transgene Sa	FACTOR IX EXPRESSION VECTORS, CELLS TRANSFORMED BY THESE VECTORS, AND PROCESS FOR THE PREPARATION OF FACTOR IX.
DK58285D0 (en)	1984-05-30	1985-02-08	Novo Industri As	PEPTIDES AND MANUFACTURING AND USING THEREOF
EP0172619A1 (en)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Novel transformant and use thereof
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (en)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	Novel csf and method of collecting same
JPS6147500A (en)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	Chimera monoclonal antibody and its preparation
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en)	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en)	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (en)	1985-03-22	1986-09-23	Novo Industri As	PEPTIDES AND PREPARATION THEREOF
FR2579224B1 (en) *	1985-03-25	1987-05-22	Genetica	PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
CA1260858A (en)	1985-03-28	1989-09-26	Lawrence S. Cousens	Expression using fused genes providing for protein product
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
JPS6229985A (en)	1985-06-17	1987-02-07	ジエネツクス・コ−ポレ−シヨン	Cloned prepro-human serum alubmin, human serum alubmin gene,plasmid containing said genes, bacteria receiving form conversion by plasmid and production of prepro-human serum alubmin using said bacteria
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (en)	1985-10-04	1994-03-16	中外製薬株式会社	Leukopenia treatment
JPS6296086A (en)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	Composite plasmid
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
DE3689123T2 (en)	1985-11-01	1994-03-03	Xoma Corp	MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
CA1295563C (en)	1985-11-01	1992-02-11	Robert T. Garvin	Production of active proteins containing cystine residues
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
CA1295566C (en)	1987-07-21	1992-02-11	Robert T. Garvin	Characterization and structure of genes for protease a and protease b from streptomyces griseus
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
JPH0780930B2 (en)	1985-12-26	1995-08-30	三井石油化学工業株式会社	Method for polymerizing α-olefin
JPH0645551B2 (en)	1986-01-07	1994-06-15	塩野義製薬株式会社	Interleukin-2 composition
EP0230980B2 (en)	1986-01-22	1996-03-20	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical agent for promoting the recovery of hemopoietic capacity
ES2036530T3 (en)	1986-01-22	1993-06-01	Chugai Seiyaku Kabushiki Kaisha	USE OF A STIMULATING FACTOR OF HUMAN GRANULOCYTIC COLONIES TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYELOGENOUS LEUKEMIA.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (en) *	1986-02-21	1989-10-20	Genetica	PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
EP0237019A3 (en)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interferon conjugate and production thereof using recombinant gene
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IT1203758B (en)	1986-03-27	1989-02-23	Univ Roma	CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DK179286D0 (en)	1986-04-18	1986-04-18	Nordisk Gentofte	INSULIN PREPARATION
US4765980A (en) *	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (en) *	1986-06-20	1989-03-01	Sclavo Spa	PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (en)	1986-07-11	1988-11-16	Sclavo Spa	YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
AU624789B2 (en)	1987-02-19	1992-06-25	Amgen, Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
JP2873012B2 (en) *	1987-04-09	1999-03-24	デルタバイオテクノロジーリミテッド	Yeast vector
DE3855504T2 (en)	1987-04-22	1997-01-23	Chiron Corp	Recombinant production of A chain polypeptides from PDGF
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
AR247761A1 (en)	1987-07-28	1995-03-31	Gist Brocades Nv	Method for producing a polypeptide in a kluyveromyces host cell, this transformed host cell and the dna sequence used
JPH0622784Y2 (en)	1987-08-04	1994-06-15	東洋シヤッター株式会社	Height adjustment device for movable center pillar for over door
JP2627899B2 (en)	1987-08-19	1997-07-09	株式会社ビタミン研究所	Production method of gene-encapsulated liposome
SE459586B (en)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
PT88641B (en)	1987-10-02	1993-04-30	Genentech Inc	METHOD FOR PREPARING A VARIETY OF ADHESION
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
JPH0811074B2 (en)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (en) *	1987-12-02	1998-08-27	株式会社ミドリ十字	Method for producing heterologous protein, recombinant DNA, transformant
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
PT89484B (en)	1988-01-22	1994-03-31	Gen Hospital Corp	GENE CLONED CODES OF FUSAO PROTEINS IG-CD4 AND ITS UTILIZATION
JPH01240191A (en) *	1988-02-16	1989-09-25	Green Cross Corp:The	Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
JPH01215289A (en)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	Production of normal human serum albumin a through gene recombination
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
DE58906966D1 (en)	1988-06-23	1994-03-24	Hoechst Ag	Mini-proinsulin, its production and use.
ZA894792B (en)	1988-06-24	1991-04-24	Dow Chemical Co	Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
CA1341373C (en)	1988-06-24	2002-07-02	Roberta C. Cheng	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
EP0387319B1 (en) *	1988-07-23	1996-03-06	Delta Biotechnology Limited	Secretory leader sequences
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (en)	1988-08-05	1994-03-04	Rhone Poulenc Sante	USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
FR2635115B1 (en)	1988-08-05	1992-04-03	Rhone Poulenc Sante	PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
AU4216689A (en)	1988-08-11	1990-03-05	California Biotechnology, Inc.	Method for stabilizing heterologous protein expression and vectors for use therein
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0436597B1 (en)	1988-09-02	1997-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (en)	1988-10-06	1990-09-10	Tonen Corp	Human serum albumin fragment
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (en)	1988-10-26	1990-05-01	Tonen Corp	Production of human serum albumin a by yeast host
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
EP0397834B1 (en)	1988-10-28	2000-02-02	Genentech, Inc.	Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
WO1990006952A1 (en)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DK105489D0 (en) *	1989-03-03	1989-03-03	Novo Nordisk As	POLYPEPTIDE
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en) *	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
ATE193541T1 (en)	1989-03-20	2000-06-15	Gen Hospital Corp	INSULINOTROPIC HORMONE
CA2489769A1 (en)	1989-03-21	1990-10-04	Philip L. Felgner	Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0392300B1 (en) *	1989-04-11	1992-08-26	BOEHRINGER INGELHEIM INTERNATIONAL GmbH	Use of at least one cytokin for the manufacture of a medicament for the systemic treatment of preneoplastic lesions
FI901810A7 (en)	1989-04-13	1990-10-14	Vascular Laboratory Inc	Plasminogen activator complex of pure pro-urokinase bound to human serum albumin via a disulfide bridge
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
ATE92107T1 (en)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
DE69031120T2 (en)	1989-05-19	1998-01-15	Genentech, Inc., South San Francisco, Calif.	HER2 EXTRACELLULAR DOMAIN
DE69024261T2 (en)	1989-05-24	1996-07-18	Merck & Co Inc	Purification and characterization of a growth factor derived from a glioma
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
WO1990015142A1 (en) *	1989-06-09	1990-12-13	Gropep Pty. Ltd.	Growth hormone fusion proteins
JPH0327320A (en)	1989-06-26	1991-02-05	Ajinomoto Co Inc	Human b cell differentiation factor pharmaceutical composition
ES2096590T3 (en)	1989-06-29	1997-03-16	Medarex Inc	BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (en) *	1989-07-26	1991-01-31	Behringwerke Ag	ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
FR2650598B1 (en)	1989-08-03	1994-06-03	Rhone Poulenc Sante	DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
CU22222A1 (en)	1989-08-03	1995-01-31	Cigb	PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
DE69007975T2 (en)	1989-08-22	1994-07-21	Immunex Corp	FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3.
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en)	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (en)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
AU638762B2 (en)	1989-10-05	1993-07-08	Optein Inc	Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (en)	1989-10-17	1993-03-26	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
EP0452457B1 (en)	1989-11-03	1997-08-20	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
DK608589D0 (en)	1989-12-01	1989-12-01	Holm Arne	CHEMICAL PROCEDURE
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
JPH03201987A (en) *	1989-12-29	1991-09-03	Tonen Corp	Human serum albumin fragment
US5116944A (en)	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
WO1996033735A1 (en)	1995-04-27	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DE69120146T2 (en)	1990-01-12	1996-12-12	Cell Genesys Inc	GENERATION OF XENOGENIC ANTIBODIES
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (en)	1990-01-24	1998-04-15	Douglas I Buckley	GLP-1 ANALOGUE USABLE IN DIABETES TREATMENT
DE69117545T2 (en) *	1990-01-25	1996-10-31	Univ Washington	Factor X-LACI hybrid protein
JPH04211375A (en)	1990-02-05	1992-08-03	Ajinomoto Co Inc	Synthetic gene and production of human serum albumin using the synthetic gene
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (en) *	1990-04-17	1994-01-21	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
WO1991018088A1 (en)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
HUT65846A (en)	1990-07-10	1994-07-28	Boehringer Ingelheim Int	Method for preparation of o-glycosylated alpha-interferons and medicinal drugs containing it
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (en)	1990-08-29	1997-09-15	Genpharm Int	PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (en)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DK0553244T4 (en)	1990-10-05	2005-08-01	Celldex Therapeutics Inc	Targeted immunostimulation with bispecific reagents
JPH07108232B2 (en)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	Method for producing peptide or protein
JPH0638771Y2 (en)	1990-10-26	1994-10-12	株式会社カンセイ	Airbag control device
WO1992008802A1 (en)	1990-10-29	1992-05-29	Cetus Oncology Corporation	Bispecific antibodies, method of production, and uses thereof
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
FR2668368B1 (en)	1990-10-30	1995-03-10	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
JPH0638771A (en)	1990-10-31	1994-02-15	Tonen Corp	Method for expressing human protein disulfide isomerase gene and method for producing polypeptide by co-expression with the gene
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
AU656353B2 (en)	1990-11-29	1995-02-02	Institut National De La Recherche Agronomique (Inra)	New variants derived from interferons of type I, production process thereof and their applications
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en)	1991-03-12	1992-09-13	Yasutaka Igari	Composition for sustained-release of erythropoietin
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en)	1991-03-28	1999-06-23	Merck & Co. Inc.	Vascular endothelial cell growth factor C subunit
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
ATE414768T1 (en)	1991-04-10	2008-12-15	Scripps Research Inst	LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
CA2108451A1 (en)	1991-04-26	1992-10-27	Beverley J. Randle	Novel antibodies, and methods for their use
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
FR2676070B1 (en)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	YEAST PROMOTER AND ITS USE.
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1992022324A1 (en)	1991-06-14	1992-12-23	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
FR2677996B1 (en)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5851795A (en) *	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en)	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (en)	1991-07-29	1993-11-09	Tonen Corp	Improved yeast expression system
EP0597010A4 (en)	1991-07-31	1996-12-27	Rhone Poulenc Rorer Int	Transgenic protein production.
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (en)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgenic rats that contain at least one human gene in their genome that is involved in blood pressure regulation
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
PT101031B (en) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY
EP0611306B1 (en) *	1991-11-08	1998-07-08	Somatogen, Inc.	Hemoglobins as drug delivery agents
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
PT1024191E (en)	1991-12-02	2008-12-22	Medical Res Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU671093B2 (en)	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (en) *	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686900B1 (en) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2372813A1 (en)	1992-02-06	1993-08-19	L.L. Houston	Biosynthetic binding protein for cancer marker
PT627940E (en)	1992-03-05	2003-07-31	Univ Texas	USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZED TUMORS
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (en) *	1992-03-19	1992-03-19	Novo Nordisk As	USE OF CHEMICAL COMPOUND
DK36492D0 (en)	1992-03-19	1992-03-19	Novo Nordisk As	PREPARATION
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
DK0598877T3 (en)	1992-06-09	2000-02-21	Hoppe Ag	Fall and door lock
EP0969016A2 (en)	1992-06-15	2000-01-05	Scios Inc.	Glucagon-like peptide and insulinotropin derivates
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (en)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	Method for producing human serum albumin
FR2694294B1 (en)	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Yeast promoter and its user.
DK0955062T3 (en)	1992-07-31	2007-09-17	Genentech Inc	Aqueous formulation containing human growth hormone
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (en) *	1992-08-14	1998-12-03	Widmar Prof Dr Tanner	Fungal cells contg. mutated DPM2 mannosyl transferase gene
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en) *	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en)	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (en) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Antitumor compositions containing taxane derivatives.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (en)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Multi-VIP fusion protein and method for preparing recombinant VIP.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
WO1994024160A2 (en)	1993-04-21	1994-10-27	Brigham And Women's Hospital	Erythropoietin muteins with enhanced activity
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
EP0699075B1 (en) *	1993-05-21	2001-12-12	Zymogenetics, Inc.	MODIFIED FACTOR VII for inhibiting vascular restenosis and platelet deposition
JP3626187B2 (en)	1993-06-07	2005-03-02	バイカルインコーポレイテッド	Plasmid suitable for gene therapy
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (en) *	1993-07-08	1993-07-08	Novo Nordisk As	PEPTIDE
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
KR100340091B1 (en)	1993-08-09	2002-09-27	베르찌 이스트반	Cancer cell sensitizing pharmaceuticals for killer cell intercellular lysis
CN1057534C (en)	1993-08-17	2000-10-18	柯瑞英-艾格公司	Erythropoietin analogs
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (en)	1993-12-08	1995-06-15	Genzyme Corporation	Process for generating specific antibodies
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
WO1995016708A1 (en)	1993-12-17	1995-06-22	Novo Nordisk A/S	Proinsulin-like compounds
DK144093D0 (en)	1993-12-23	1993-12-23	Novo Nordisk As
DE69534347T2 (en)	1994-01-31	2006-05-24	Trustees Of Boston University, Boston	Libraries of polyclonal antibodies
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (en)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en)	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
EP0769963A4 (en)	1994-07-27	1999-07-28	Commw Scient Ind Res Org	Polyepitope vaccines
JPH0853500A (en)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	Fusion protein and gene encoding the protein
JPH0851982A (en)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	Modified gene encoding human serum albumin
JPH0859509A (en)	1994-08-16	1996-03-05	Teijin Ltd	Cytomegalovirus antigenemia therapeutic agent and cytomegalovirus infectious disease therapeutic agent
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726471B1 (en) *	1994-11-07	1997-01-31	Pf Medicament	PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
FR2726576B1 (en)	1994-11-07	1997-01-31	Pf Medicament	PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
JP4046349B2 (en)	1994-11-07	2008-02-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Tumor necrosis factor-γ
AT403167B (en)	1994-11-14	1997-11-25	Immuno Ag	SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
AU4415796A (en)	1994-12-07	1996-06-26	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
EP0796335A1 (en)	1994-12-07	1997-09-24	Bionebraska, Inc.	Production of peptides using recombinant fusion protein constructs
DE69534265T2 (en) *	1994-12-12	2006-05-04	Beth Israel Deaconess Medical Center, Inc., Boston	CHIMERIC CYTOKINS AND ITS USE
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
ATE234625T1 (en)	1994-12-23	2003-04-15	Novo Nordisk As	GLP-1 EXTENDED-DURING COMPOSITIONS
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
JP2758154B2 (en)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	Liquid preparations containing interferon
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
JPH11507205A (en)	1995-04-27	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	Human tumor necrosis factor receptor
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
EP0741188A3 (en)	1995-05-05	1999-07-14	Eli Lilly And Company	Single chain insulin with high bioactivity
AU3134695A (en)	1995-05-05	1996-11-21	Human Genome Sciences, Inc.	Human chemokine beta-8, chemokine beta-1 and macrophage infl ammatory protein-4
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US5741815A (en)	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (en)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Active ingredient and agent for parenteral nutrition
JPH0995455A (en)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	Renal function improving agent
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en)	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
DE69632062T2 (en)	1995-11-02	2004-11-18	Schering Corp.	CONTINUOUS, LOW-DOSE CYTOKINE INFUSION THERAPY
US6048964A (en)	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO1997026321A2 (en)	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2978435B2 (en)	1996-01-24	1999-11-15	チッソ株式会社	Method for producing acryloxypropyl silane
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
DE19639601A1 (en)	1996-02-28	1997-09-04	Bayer Ag	Parapox viruses that contain foreign DNA, their production and their use in vaccines
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE69740176D1 (en)	1996-03-01	2011-05-26	Novo Nordisk As	Appetite inhibiting peptide, composition and use
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (en) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	Method for culturing microorganisms with methanol metabolism
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
ATE241695T1 (en)	1996-03-13	2003-06-15	Delta Biotechnology Ltd	FERMENTATION CONTROL SYSTEMS
WO1997033998A1 (en)	1996-03-14	1997-09-18	The Immune Response Corporation	Targeted delivery of genes encoding interferon
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997034997A1 (en) *	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Human endometrial specific steroid-binding factor i, ii and iii
CA2248868A1 (en)	1996-03-22	1997-09-25	Human Genome Sciences, Inc.	Apoptosis inducing molecule ii
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
WO1997039132A1 (en)	1996-04-16	1997-10-23	University Of Miami	Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
US6497878B1 (en) *	1996-04-23	2002-12-24	Chugai Seiyaku Kabushiki Kaisha	Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
ES2151277T3 (en) *	1996-05-22	2000-12-16	Protarga Inc	COMPOSITIONS INCLUDING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE.
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
EP0917566B1 (en) *	1996-06-11	2004-09-22	Roche Diagnostics GmbH	Recombinant blood-coagulation proteases
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
WO1998002543A1 (en)	1996-07-15	1998-01-22	Chugai Research Institute For Molecular Medicine, Inc.	Novel vegf-like factors
AR008077A1 (en)	1996-07-26	1999-12-09	Talarico Salinas Laura Beatriz	A FUSION POLYPEPTIDE OR A SALT OF THE SAME, ITS USE, A PROCESS TO PREPARE THEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND A VECTOR.
WO1998005782A1 (en)	1996-08-02	1998-02-12	Zymogenetics, Inc.	Testis-specific insulin homolog polypeptides
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
ATE412740T1 (en)	1996-08-16	2008-11-15	Human Genome Sciences Inc	HUMAN ALPHA ENDOKINE
ES2308787T3 (en)	1996-08-16	2008-12-01	Schering Corporation	ANTIGENS OF MAMPHERE CELL SURFACE; RELATED REAGENTS.
EP1283268A3 (en)	1996-08-23	2004-01-02	Ludwig Institute For Cancer Research	Recombinant vascular endothelial cell growth factor D (VEGF-D)
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
AU4199597A (en)	1996-09-09	1998-04-02	Novo Nordisk A/S	A cdna and peptide with relation to cancer and weight loss
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
AU7364696A (en) *	1996-09-18	1998-04-14	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
KR20060079258A (en)	1996-10-18	2006-07-05	제넨테크, 인크.	Anti-ER2 antibody
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
PT939804E (en)	1996-10-25	2005-11-30	Human Genome Sciences Inc	ALPHA NEUTROQUIN
JPH10134761A (en)	1996-10-30	1998-05-22	Ebara Corp	Ion implantation apparatus and ion implantation method
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
EP1306092A3 (en)	1996-11-05	2003-05-07	Eli Lilly & Company	Use of GLP-1 and analogs administered peripherally, in regulation of obesity
UA65549C2 (en)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
DE69732572T2 (en)	1996-11-12	2005-12-29	Novo Nordisk A/S	USE OF GLP-1 PEPTIDES
CA2722378C (en)	1996-12-03	2015-02-03	Amgen Fremont Inc.	Human antibodies that bind tnf.alpha.
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
JP2001505060A (en)	1997-01-14	2001-04-17	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Tumor necrosis factor receptor 5
EP0954589A1 (en)	1997-01-24	1999-11-10	Novo Nordisk A/S	Synthetic leader peptide sequences
PT1012274E (en)	1997-01-28	2007-08-14	Craig A Rosen	Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
WO1998032466A1 (en)	1997-01-29	1998-07-30	Polymasc Pharmaceuticals Plc	Pegylation process
EP0981635A1 (en)	1997-02-13	2000-03-01	Applied Phytologics, Inc.	Production of mature proteins in plants
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en)	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
WO1999019339A1 (en) *	1997-10-09	1999-04-22	Human Genome Sciences, Inc.	53 human secreted proteins
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
US5981488A (en)	1997-03-31	1999-11-09	Eli Lillly And Company	Glucagon-like peptide-1 analogs
BRPI9809391B8 (en)	1997-04-14	2021-05-25	Amgen Res Munich Gmbh	process for producing an anti-human antigen receptor, human antibody and pharmaceutical composition
MY118835A (en) *	1997-04-18	2005-01-31	Ipsen Pharma Biotech	Sustained release compositions and the process for their preparation
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
CA2292790A1 (en)	1997-05-30	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2295991A1 (en)	1997-06-11	1998-12-17	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr9
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
ES2208798T3 (en)	1997-09-01	2004-06-16	Aventis Pharma Deutschland Gmbh	RECOMBINANT HUMAN ERYTHROPOYETIN WITH AN ADVANTAGE GLICOSILATION PROFILE.
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2186660T3 (en)	1997-09-21	2003-05-16	Schering Corp	COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.
EP1426058A3 (en)	1997-09-23	2004-07-28	Dr. Rentschler Biotechnologie GmbH	Liquid interferon-beta formulations
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
CA2309541C (en)	1997-11-03	2011-01-11	Human Genome Sciences, Inc.	Vegi, an inhibitor of angiogenesis and tumor growth
WO1999028346A1 (en)	1997-12-03	1999-06-10	Roche Diagnostics Gmbh	Erythropoietin with high specific activity
EP1049486A4 (en)	1997-12-05	2006-01-04	Lilly Co Eli	Glp-1 formulations
ES2590912T3 (en)	1997-12-08	2016-11-24	Merck Patent Gmbh	Heterodimeric fusion proteins useful for targeted immunotherapy and general immune system stimulation
AU738804B2 (en) *	1997-12-08	2001-09-27	Bristol-Myers Squibb Company	Novel salts of metformin and method
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (en)	1997-12-29	2000-05-01	김충환	Method for preparing human insulin precursor
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
EP1054594B1 (en)	1998-02-13	2007-07-04	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and glp-1
WO1999043706A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
WO1999047160A1 (en)	1998-03-13	1999-09-23	Novo Nordisk A/S	Stabilized aqueous peptide solutions
WO1999047161A1 (en)	1998-03-19	1999-09-23	Bionebraska, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (en)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-viral effects of propolis through inhibition of viral nucleic acid polymerases
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
AU3047299A (en)	1998-04-13	1999-11-01	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (en)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Novel microsphere composition
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
CN1119352C (en)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	Express and purification of human serum albumin in pichia
AU766597B2 (en)	1998-05-15	2003-10-16	Schering Corporation	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (en)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
MXPA00012286A (en)	1998-06-12	2002-10-17	Bionebraska Inc	GLUCAGON-LIKE PEPTIDE-1 IMPROVES beta-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE.
DE69933216T2 (en) *	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	ERYTHROPOIETIN ANALOG HUMAN SERUM ALBUMIN FUSION PROTEIN
CN1105727C (en)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	Production method of recombinant human serum albumin
CA2335617C (en)	1998-06-24	2009-12-15	Novirio Pharmaceuticals Limited	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
IL140341A0 (en)	1998-06-30	2002-02-10	Novo Nordisk As	Seeding crystals for preparation of peptides or proteins
AU8508398A (en)	1998-07-15	2000-02-07	Wisconsin Alumni Research Foundation	Treatment of diabetes with synthetic beta cells
ATE251465T1 (en)	1998-07-31	2003-10-15	Novo Nordisk As	IN-VITRO STIMULATION OF BETA CELL PRODUCTION
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
DE69941510D1 (en)	1998-08-10	2009-11-19	Us Gov Nat Inst Health	DIFFERENTIATION OF NON-INSULIN IN INSULIN-PRODUCING CELLS BY GLP-1 AND EXENDIN-4 AND THEIR USE
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
BR9913284A (en)	1998-08-28	2001-05-15	Lilly Co Eli	Methods for administering insulinotropic peptides
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CA2345382A1 (en)	1998-10-16	2000-04-27	Immunex Corporation	Inhibitors of platelet activation and recruitment
AU774989B2 (en)	1998-10-23	2004-07-15	Amgen, Inc.	Methods and compositions for the prevention and treatment of anemia
ATE365210T1 (en)	1998-10-30	2007-07-15	Novozymes As	GLYCOSYLATED PROTEINS WITH REDUCED ALLERGENITY
EP1135493A2 (en)	1998-11-30	2001-09-26	Eli Lilly And Company	Erythropoietic compounds
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
DE69928006T2 (en)	1998-12-22	2006-07-13	Eli Lilly And Co., Indianapolis	STABILITY LIQUID COMPOSITIONS OF GLUCAGON-SIMILAR PEPTIDE-1
US20030009013A1 (en) *	1998-12-30	2003-01-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
EP1175440A1 (en)	1999-04-09	2002-01-30	Human Genome Sciences, Inc.	48 human secreted proteins
JP2002542183A (en)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	Moldable dry pharmaceutical formulation
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
DE19921537A1 (en)	1999-05-11	2000-11-23	Dieter Hoersch	Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
BR0010750A (en)	1999-05-17	2002-02-26	Conjuchem Inc	Long-acting insulinotropic peptides
RU2262510C9 (en)	1999-05-19	2006-04-20	Лексиген Фармасьютикэлс Корп.	Fused protein eliciting biological activity of interferon-alpha, dimeric fused protein, pharmaceutical composition comprising thereof, dna molecule (variants) and method for targeting interferon-alpha into liver tissue
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
EP1849475A1 (en)	1999-06-21	2007-10-31	Eli Lilly & Company	Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythopintin derivatives
US20020048571A1 (en)	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
CA2376641A1 (en)	1999-07-19	2001-01-25	Aaron Morris	Chimeric polypeptides of serum albumin and uses related thereto
EP1203005A4 (en)	1999-08-17	2004-11-24	Human Genome Sciences Inc	25 human secreted proteins
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
BR0014945A (en)	1999-10-21	2004-08-31	Monsanto Co	Posttranslational modification of recombinant proteins produced in plants
AU1226901A (en)	1999-10-22	2001-05-08	Amgen, Inc.	Biodegradable microparticles with novel erythropoietin stimulating protein
ATE381343T1 (en)	1999-11-03	2008-01-15	Novo Nordisk As	USE OF A GROWTH HORMONE OR AN AGENT THAT PROMOTES GROWTH HORMONES SECRETION FOR APPETITE SUPPRESSION OR SATURATION INDUCTION
CA2324801A1 (en)	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
CA2391080A1 (en)	1999-11-12	2001-05-25	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Erythropoietin forms with improved properties
CA2392615A1 (en)	1999-12-06	2001-06-07	The General Hospital Corporation	Pancreatic stem cells and their use in transplantation
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en)	2000-01-18	2003-01-02	Pfizer Products Inc.	Uses of agrp-melanocortin receptor binding modulating compounds
MXPA02007231A (en)	2000-01-27	2002-12-09	Lilly Co Eli	Process for solubilizing glucagon like peptide 1 compounds.
AU2001228327A1 (en)	2000-01-31	2001-08-14	Novo-Nordisk A/S	Crystallisation of a glp-1 analogue
CN1487836A (en)	2000-03-14	2004-04-07	埃米林药品公司	Effects of glucagon-like peptide 1(7-36) on motility of gastric antrum pyloric duodenum
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
PT1274728E (en)	2000-04-21	2008-06-20	Amgen Inc	Methods and compositions for the prevention and treatment of anemia
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
ME00673B (en) *	2000-05-15	2011-12-20	Hoffmann La Roche	New pharmaceutical composition
US20020061838A1 (en)	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
JP4716641B2 (en)	2000-06-16	2011-07-06	イーライリリーアンドカンパニー	Glucagon-like peptide-1 analog
EP1970072A1 (en)	2000-09-18	2008-09-17	Sanos Bioscience A/S	Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en)	2000-12-04	2002-06-18	Biovitrum Ab	Novel method and use
IL155812A0 (en)	2000-12-07	2003-12-23	Lilly Co Eli	Glp-1 fusion proteins
AU3938402A (en)	2000-12-13	2002-06-24	Lilly Co Eli	Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en)	2000-12-13	2002-06-24	Eli Lilly And Company	Amidated glucagon-like peptide-1
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
KR100399337B1 (en)	2001-02-07	2003-09-26	드림바이오젠 주식회사	Method for Cell-free Protein Post-translational Modification
EP1949908A1 (en)	2001-03-07	2008-07-30	Novo Nordisk A/S	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20060084794A1 (en)	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (en)	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
WO2002097038A2 (en)	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
AU2002308706A1 (en)	2001-06-01	2002-12-16	Eli Lilly And Company	Glp-1 formulations with protracted time action
EP1397124B1 (en)	2001-06-20	2006-11-29	Merck Sante	Use of antidiabetics for making a medicine with cicatrizing effect
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
ATE408414T1 (en)	2001-07-31	2008-10-15	Us Gov Health & Human Serv	GLP 1 EXENDIN 4 PEPTIDE ANALOGUES AND THEIR USES
EP1572885A2 (en)	2001-08-08	2005-09-14	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
EP1423136A4 (en)	2001-08-10	2007-07-25	Epix Pharm Inc	POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
AU2002332041A1 (en)	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2411007T3 (en) *	2001-10-10	2013-07-04	Novo Nordisk A/S	Remodeling and glycoconjugation of peptides
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
WO2003059934A2 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003054182A2 (en)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production of butyrylcholinesterases in transgenic mammals
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
AU2003210806A1 (en)	2002-03-05	2003-09-22	Eli Lilly And Company	Heterologous g-csf fusion proteins
DE60336555D1 (en) *	2002-06-21	2011-05-12	Novo Nordisk Healthcare Ag	PEGYLATED GLYCO FORMS OF FACTOR VII
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
AU2004216476B2 (en) *	2003-02-27	2009-01-08	Takeda Pharmaceutical Company Limited	Method for the validatable inactivation of pathogens in a biological fluid by irradiation
DK1641823T3 (en)	2003-06-12	2011-12-12	Lilly Co Eli	GLP-1 analog fusion proteins
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
WO2007021494A2 (en)	2005-08-12	2007-02-22	Human Genome Sciences, Inc.	Albumin fusion proteins
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Albumin fusion proteins
US9486507B2 (en) *	2011-06-10	2016-11-08	Biogen Ma Inc.	Pro-coagulant compounds and methods of use thereof

2001
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/en not_active Expired - Lifetime
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/en active Pending
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/en active Pending
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Ceased
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Ceased
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/en active Pending
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/en active
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en not_active Ceased
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Ceased
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en not_active Ceased
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Ceased
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en not_active Ceased
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/en active Pending
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/en active Pending
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/en active Pending
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/en active Pending
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/en active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/en active Pending
2016
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/en active Active
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9849162B2 (en)	2017-12-26
US6926898B2 (en)	2005-08-09
AU2001274809A1 (en)	2001-10-30
US20080269128A1 (en)	2008-10-30
WO2001079443A3 (en)	2002-02-21
US20180200346A1 (en)	2018-07-19
EP1278544A2 (en)	2003-01-29
EP2236152A1 (en)	2010-10-06
EP2216409B1 (en)	2014-12-03
EP1803730A1 (en)	2007-07-04
US10080785B2 (en)	2018-09-25
EP1276756A4 (en)	2004-06-09
JP2014057589A (en)	2014-04-03
CA2405912A1 (en)	2001-10-18
WO2001079442A2 (en)	2001-10-25
EP1278767A1 (en)	2003-01-29
EP2298355A3 (en)	2011-06-29
AU2001266557A1 (en)	2001-10-23
DK2216409T3 (en)	2015-01-05
EP1274720A4 (en)	2004-08-18
EP2298355A2 (en)	2011-03-23
FR16C0043I1 (en)	2016-12-09
US20050266533A1 (en)	2005-12-01
US20120252732A1 (en)	2012-10-04
DK2236152T3 (en)	2014-07-07
EP1274720A1 (en)	2003-01-15
JP2003531590A (en)	2003-10-28
JP2004506407A (en)	2004-03-04
JP2003530852A (en)	2003-10-21
US20140004095A1 (en)	2014-01-02
US6905688B2 (en)	2005-06-14
JP2003530839A (en)	2003-10-21
EP2213743A1 (en)	2010-08-04
US20080269126A1 (en)	2008-10-30
US20080269127A1 (en)	2008-10-30
AU2001259063A1 (en)	2001-10-30
US20050266532A1 (en)	2005-12-01
EP2067488A1 (en)	2009-06-10
US9775888B2 (en)	2017-10-03
US8946156B2 (en)	2015-02-03
EP1274719A4 (en)	2004-05-19
AU2001259066A1 (en)	2001-10-30
US20040171123A1 (en)	2004-09-02
US20110280830A9 (en)	2011-11-17
WO2001077137A1 (en)	2001-10-18
AU2001261024A1 (en)	2001-10-30
CA2405550A1 (en)	2001-10-25
EP2216409A1 (en)	2010-08-11
CA2747325A1 (en)	2001-10-25
US7785599B2 (en)	2010-08-31
WO2001079444A2 (en)	2001-10-25
JP2003530838A (en)	2003-10-21
US20140010798A1 (en)	2014-01-09
EP1278767A4 (en)	2003-11-12
US20130266553A1 (en)	2013-10-10
EP2275557A1 (en)	2011-01-19
WO2001079444A3 (en)	2002-05-23
US7482013B2 (en)	2009-01-27
CA2405709A1 (en)	2001-10-25
AU2001262942A1 (en)	2001-10-30
FR16C0043I2 (en)	2020-04-10
CA2405563A1 (en)	2001-10-25
EP2357008A1 (en)	2011-08-17
AU2001264563A1 (en)	2001-10-30
WO2001079271A9 (en)	2002-02-28
WO2001079442A3 (en)	2002-06-06
US20080269125A1 (en)	2008-10-30
CA2405557A1 (en)	2001-10-25
JP2003530847A (en)	2003-10-21
WO2001079480A1 (en)	2001-10-25
EP2206720A1 (en)	2010-07-14
EP1832599A3 (en)	2007-11-21
WO2001079443A2 (en)	2001-10-25
EP1276849A4 (en)	2004-06-09
US20090285816A9 (en)	2009-11-19
US20080131399A1 (en)	2008-06-05
US9821039B2 (en)	2017-11-21
ES2529300T3 (en)	2015-02-18
US20070287173A9 (en)	2007-12-13
CA2405525A1 (en)	2001-10-25
US20030219875A1 (en)	2003-11-27
WO2001079480A9 (en)	2003-09-18
EP1276856A1 (en)	2003-01-22
EP2236152B1 (en)	2014-06-04
EP1276856A4 (en)	2004-06-09
WO2001079258A9 (en)	2002-02-28
EP1276849A2 (en)	2003-01-22
EP2311872A1 (en)	2011-04-20
WO2001077137A9 (en)	2002-05-02
US6994857B2 (en)	2006-02-07
US20080267962A1 (en)	2008-10-30
US20100189686A1 (en)	2010-07-29
WO2001079271A1 (en)	2001-10-25
US7507414B2 (en)	2009-03-24
ES2484966T3 (en)	2014-08-12
EP2295456A1 (en)	2011-03-16
EP1276756A1 (en)	2003-01-22
EP1983055A1 (en)	2008-10-22
US20040010134A1 (en)	2004-01-15
US20120141415A1 (en)	2012-06-07
US20030199043A1 (en)	2003-10-23
US20030171267A1 (en)	2003-09-11
JP2003530846A (en)	2003-10-21
US20120141449A1 (en)	2012-06-07
WO2001079258A1 (en)	2001-10-25
US20080261877A1 (en)	2008-10-23
EP1274719A2 (en)	2003-01-15
EP1278544A4 (en)	2004-08-18
EP1832599A2 (en)	2007-09-12
CA2405557C (en)	2013-09-24
EP2267026A1 (en)	2010-12-29
JP2011217750A (en)	2011-11-04
US20030125247A1 (en)	2003-07-03
CA2405701A1 (en)	2001-10-25

Publication	Publication Date	Title
BE2016C059I2 (en)	2020-08-20
BE2014C019I2 (en)	2021-01-29
BE2010C009I2 (en)	2020-01-30
BE2009C057I2 (en)	2021-01-28
JP2000347946A5 (en)	2007-05-17
BRPI0110940B8 (en)	2021-05-25
JP2003514716A5 (en)	2007-12-27
BE2010C040I2 (en)	2020-01-30
AU2000236813A8 (en)	2001-11-15
JP2001308306A5 (en)	2007-06-07
JP2002195162A5 (en)	2007-02-08
BR0112866A2 (en)	2009-12-08
JP2002104386A5 (en)	2007-11-01
JP2001309113A5 (en)	2006-02-09
IN192825B (en)	2004-05-22
IN191958B (en)	2004-01-24
BRPI0000763B8 (en)	2021-06-22
AU2000270757A8 (en)	2002-04-18
AU2000274567A8 (en)	2002-05-02
CN3144928S (en)	2000-04-05
AU2000266391A8 (en)	2002-05-23
CN3143841S (en)	2000-03-29
CN3143422S (en)	2000-03-29
CN3146242S (en)	2000-04-19
CN3141860S (en)	2000-03-15